


Healthcare News Roundup: Biopharmaceutical
HSMN NewsFeed - 27 Jul 2021
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
Umoja Biopharma Expands Management Team with Key Hires in Research and Business Development
HSMN NewsFeed - 23 Jul 2021
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim
HSMN NewsFeed - 22 Jul 2021
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
HSMN NewsFeed - 19 Jul 2021
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
Nektar Appoints Dimitry S.A. Nuyten, M.D., Ph.D., as Senior Vice President and Chief Medical Officer
HSMN NewsFeed - 13 Jul 2021
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing
HSMN NewsFeed - 8 Jul 2021
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
Elevar Therapeutics Announces New Appointments to Strengthen its Executive and Senior Leadership Teams
HSMN NewsFeed - 8 Jul 2021
Theolytics expands Series A financing and welcomes M Ventures as a new investor
Theolytics expands Series A financing and welcomes M Ventures as a new investor
HSMN NewsFeed - 5 Jul 2021
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
HSMN NewsFeed - 1 Jul 2021
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
Windtree Appoints Diane Carman, Esq. as Senior Vice President and General Counsel
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
HSMN NewsFeed - 23 Jun 2021
Evrysdi(TM) Approved in Japan for the Treatment of Spinal Muscular Atrophy
Evrysdi(TM) Approved in Japan for the Treatment of Spinal Muscular Atrophy
HSMN NewsFeed - 22 Jun 2021
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
Valeo Pharma Announces Commercial Launch of Enerzair(R) Breezhaler(R) and Atectura(R) Breezhaler(R)
HSMN NewsFeed - 18 Jun 2021
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies
HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
HSMN NewsFeed - 17 Jun 2021
Irrimax Receives FDA Clearance for Irrisept(R) as an Antimicrobial Wound Lavage for US Market
Irrimax Receives FDA Clearance for Irrisept(R) as an Antimicrobial Wound Lavage for US Market
HSMN NewsFeed - 17 Jun 2021
Lilly Launches Think Talk Treat Migraine(TM) to Help Improve Diagnosis and Treatment of Migraine
Lilly Launches Think Talk Treat Migraine(TM) to Help Improve Diagnosis and Treatment of Migraine
HSMN NewsFeed - 16 Jun 2021
Pharmaceutical Associates, Inc. appoints Dr. Suketu Sanghvi as Chief Scientific Officer
Pharmaceutical Associates, Inc. appoints Dr. Suketu Sanghvi as Chief Scientific Officer
HSMN NewsFeed - 16 Jun 2021
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members
HSMN NewsFeed - 16 Jun 2021
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
KAHR Announces $46.5 Million Financing to Advance its Multifunctional Immunotherapeutic Pipeline
HSMN NewsFeed - 14 Jun 2021
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
FDA Clears LPCN 1154 IND Application for a Phase 2 Postpartum Depression Study
HSMN NewsFeed - 8 Jun 2021
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
Umoja Biopharma Announces Appointment of David Fontana, Ph.D., as Chief Business and Strategy Officer
